# Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment

> **NCT02253251** · — · RECRUITING · sponsor: **MiraKind** · enrollment: 15000 (estimated)

## Conditions studied

- Cancer

## Interventions

- **GENETIC:** KRAS-variant and microRNA binding site mutation testing

## Key facts

- **NCT ID:** NCT02253251
- **Lead sponsor:** MiraKind
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2014-09
- **Primary completion:** 2030-12
- **Final completion:** 2035-09
- **Target enrollment:** 15000 (ESTIMATED)
- **Last updated:** 2025-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02253251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02253251, "Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02253251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*